skinny.

Latest / Investing, Markets & Money

Biotech Investing in 2026: M&A Boom, FDA Shakeup & the Cancer Drug That Could Double Survival Rates | Ep.163

Is biotech finally back? In this episode, Stuart sits down with Ailsa Craig, co-manager of the International Biotechnology Trust from Schroders, a £1bn+ closed-ended fund with a 4% dividend yield and 30+ years of history, to break down everything self-directed investors need to know about the biotech sector right now. They cover: ✅ Why biotech has been in a prolonged bear market (and why that's changing) ✅ The M&A wave sweeping the sector — and how IBT is benefiting ✅ FDA uncertainty under the new US administration ✅ AI's real (and realistic) impact on drug development timelines ✅ The…

The skinny

The skinny isn't ready yet — notes appear once the transcript is processed.